Hepatosplenic T-cell lymphoma (HSTL) is a rare entity mostly derived from γδ T cells that shows a fatal outcome. Its pathogenesis remains largely unknown. HSTL samples (7γδ, 2αβ) and the DERL2 HSTL-cell line were subject to combined gene expression profiling and array-based containing SYK and AIM1 genes, respectively. The current study identifies a distinct molecular signature for HSTL and highlights oncogenic pathways which offer rationale for exploring new therapeutic options such as Syk inhibitors and demethylating agents.
INTRODUCTION
Hepatosplenic T-cell lymphoma (HSTL), originally described as hepatosplenic γδ T cell lymphoma, is a rare lymphoma entity with peculiar clinical presentation -hepatosplenomegaly without significant lymphadenopathy -and pathological features -intrasinusal/sinusoidal infiltration by neoplastic Τ cells in the bone marrow, spleen and liver [1] [2] [3] . The disease occurs predominantly in young adults, in association with a setting of long-term immunosuppression in solid organ transplant recipients or with prolonged antigenic stimulation 4 . Cases have also been reported in children treated by azathioprine and infliximab for Crohn's disease 5 . While most HSTL are derived from the γδ subset, a few similar cases with an αβ phenotype have also been described 6, 7 , and the simplified designation "hepatosplenic T-cell lymphoma" was favored in the latest World Health Organization classification 8 . HSTL is associated with a recurrent isochromosome 7q and less often, trisomy 8 9 , but its pathogenesis remains largely unknown.
Despite relatively innocuous cytology, the disease is highly aggressive with an almost constant fatal outcome and a median overall survival barely exceeding one year 4 . Occasional long survivors have been reported and few patients respond to cytarabine or deoxycoformycin 4, 10 .
Therapeutic strategies curative in a significant proportion of other aggressive subtypes of lymphoma, have proved to be ineffective in HSTL and efficient treatment modalities remain to be defined.
Over the past years, genome-wide molecular profiling studies have contributed significant insights to the pathobiology of several T-cell lymphoma entities [11] [12] [13] [14] and brought informative data on the multiple molecular subgroups in PTCL, not otherwise specified (PTCL,NOS) 15, 16 . In that respect, data on HSTL are scarce 13, 17 . In the current study, we analyzed a series of HSTL samples in relation to normal γδ cells, PTCL,NOS and extranodal NK/T-cell lymphoma, nasal-type (NKTCL), another entity derived from cytotoxic lymphocytes of the innate immune system. The aim of the study was to (1) characterize the molecular signature of HSTL, (2) identify potential candidate pathways relevant to pathogenesis, and (3) search for biomarkers useful in the diagnostic purposes or in the future targeted therapies.
PATIENTS, MATERIALS AND METHODS

Patient characteristics and tumor samples
Nine HSTL patients with high quality RNA and/or DNA extracted from frozen tumor samples were selected for this study. All patients had spleen, liver and bone marrow involvement without lymphadenopathies. Three patients had been included in previous reports 4, 9 . The main clinical, phenotypic and molecular characteristics are summarized in Table 1 . The tumor samples, comprised six splenic tissue samples and three cell suspensions (from spleen, bone marrow and blood), two of which were enriched in tumor cells (samples HSTL_01 and HSTL_09). All cases were reviewed by three hematopathologists (L.d.L, Y.H. and P.G.) and diagnosed according to the WHO criteria 8 . The tumor cells had a CD3+, CD2+, CD5-, TiA1+, GzmBimmunophenotype and were negative for EBV. T-cell receptor (TCR )lineage was determined by immunohistochemistry and/or flow cytometry for TCRβ and TCRδ chain expression and by GCclamp multiplex PCR for TCRγ and/or δ chain rearrangements ((PCR)-δ-DGGE procedure) 18 . In total, seven cases with a δTCR1+, βF1-immunophenotype and/or a biallelic rearrangement of the TCRδ chain 18, 19 , were classified as γδ HSTL and two cases with a δTCR1-, βF1+ phenotype as αβ HSTL. Four of seven investigated cases disclosed isochromosome 7q.
Twelve additional HSTL cases were selected for validations (10 formalin-fixed tissues for immunohistochemistry and 2 frozen samples for RT-PCR analyses).
The study was approved by the institutional review board "Comité de Protection des Personnes
Ile de France IX", Créteil, France CPP N°08-009 (06/05/08).
Cell lines and normal γδ T cells
Eight samples of normal peripheral blood activated γδ T cells (6 from Correia 20 and 2 from Zhang 21 ) and 3 samples of normal resting γδ T cells (from Correia 20 ) were used for comparison.
Normal γδ T cells sorted using magnetic anti-TCRγ/δ microbeads kit (Miltenyi Biotec, Bergisch
Gladbach, Germany) from 3 spleens removed for benign conditions were also obtained for qRT-PCR validation. DERL2, a γδ cell line derived from HSTL 22 , was cultured in IMDM supplemented with 2 mM L-glutamine and 20% heat-inactivated human serum (Invitrogen, Carlsbad, CA) in the presence of recombinant human interleukin (IL)-2 (100 U/ml, Laboratoires
Chiron, Amsterdam). Centrifugated pellets of DERL2 cells were fixed in ethanol to construct paraffin-embedded blocks 14 .
Microarray procedures
Microarray analyses, from extraction to labeling and hybridization, were performed as previously reported 11, 14 .
Gene expression analyses
HG-U133-plus-2.0 Affymetrix array data were obtained for nine HSTL and the DERL-2 cell line (Table 1 ) and deposited to ArrayExpress under accession number E-MTAB-638. HG-U133-plus-2.0 profiles of 42 PTCL-NOS, 23 AITL, 23 NKTCL and 3 HSTL previously reported by our group (E-TABM-783, E-TABM-702, n=40) 11, 14 and others (GSE19067, GSE6338, n=51) 12, 13 were used for analyses. Control samples (8 activated γδ T-cells, 3 resting γδ T-cells, 18 B-cells, 6 spleens and 9 lymph nodes) were collected by us (n=6) or from public sources (E-MEX-1601,   GSE13906, GSE12195, GSE15271, GSE7307) 20, 21, 23, 24 . Affymetrix raw data of all samples were normalized in batch using RMA algorithm. The clustering analysis of the 50 tumor samples from our series was performed as already described 14 . We used moderate T-tests to identify genes 6 differentially expressed between two groups of samples and AUC criteria to identify discriminant genes. KEGG and Biocarta pathways (and related genes) were obtained from ftp://ftp.genome.ad.jp/pub/kegg/pathways/hsa and http://www.biocarta.com. Pathways were ranked according to the scores of three different algorithms including globaltest, SAM-GS and GSA. Methodological details are given in the Supplementary Materials and Methods (Method S1).
Array-based comparative genomic hybridization
DNAs extracted from 7 HSTL and DERL2 cell line were hybridized on Agilent Sureprint CGH array 4 x 180 k covering over 170,000 coding and non-coding human sequences. CGH array raw Cy3/Cy5 intensities were quantile normalized independently for each sample; smoothing was performed using tilingArray R package, copy number status (Gain/Loss) determination in the smoothed segments was done as previously reported 14 . Details are given as supplemental (Method S1).
Quantitative reverse-transcriptase PCR analysis of candidate genes
The expression level of candidate genes (FOS, FOSB, AIM1, RHOB, ABCB1, VAV3, KIR3DS1, S1PR5) identified in gene expression analysis was determined by TaqMan ® quantitative reversetranscriptase PCR (qRT-PCR) (Applied Biosystems, Foster City, CA) in 11 primary HSTL tumors (including the 9 cases submitted to GEP analysis), the DERL2 cell line and 3 normal splenic γδ T cell samples as control. All primers and probes were purchased from Applied
Biosystems and the gene expression was measured using Mastercycler ® ep realplex 2S system (Eppendorf, Hamburg, Germany). Quantifications were done in duplicate and mean values and standard deviation were calculated for each transcript as previously described 25 .
Immunohistochemical analysis of selected candidate genes
Immunohistochemistry was performed on deparaffinized tissue sections using a standard indirect avidin-biotin immunoperoxidase method. After appropriate antigen retrieval, sections were stained for FosB (Cell Signaling Technology, Danvers, MA); CD56, CD163 and GSTP1
(Novocastra-Leica, Wetzlar, Germany); β-catenin (BD Biosciences, San Diego, USA); Bcl-10 (Zymed, San Francisco, USA), ICAM-1 (Atlas Antibodies, Stockolm, Sweden), VCAM-1 and Syk (Santa Cruz Biotechnology, Santa Cruz, USA), Blimp-1 (BioLegend UK Ltd, Cambridge, UK). For granzyme H (gzm H)(4G5) a tyramide signal amplification system was applied, as previously described 14 . Adequate controls were included.
Methylation analysis of AIM1
Two µg of genomic DNA were treated with bisulfite using the Epitect ® Bisulfite Kit (Qiagen, Courtaboeuf, France) according to manufacturer's protocol. Nested bisulfite-specific PCR for the 2 CpG islands of AIM1 was performed on DERL2 cells DNA (details, primers and PCR programs used are given in Supplemental Methods (Method S1)). PCR products were cloned in plasmid using TOPO TA cloning kit for sequencing (Invitrogen). Ten clones for each CpG islands were screened and sequenced on the ABI 3130X1 genetic analyser (Applied Biosystems). 
5-Aza
Immunoblot analysis
Total cell proteins extracted from normal blood T cells [purified after CD2 magnetic beads selection and activated or not by CD3 (1µg/ml), CD28 (1µg/ml) and IL2 (100U/ml)], overnight serum deprivated DERL2 cells with or without CD3, CD28 and IL2 activation and overnight serum deprivated SUDHL4 cells with or without BCR stimulation (anti-Fab'2, 4µg/ml) were analyzed for the expression of Syk, phospho-Syk (Tyr525/526)(C87C1) (Cell Signaling technology) and β-actin (Sigma Aldrich). Immunoblotting was done as previously described 25 .
Apoptosis assay with a Syk inhibitor
Normal activated γδ T cells were obtained as previously described 26 table S1 ).
Comparison of HSTL gene expression profiles with that of either PTCL,NOS or NKTCL revealed similar proportions of differentially expressed genes (H1 Proportion, see Method S1) of 37% and 39% respectively), however in unsupervised clustering analysis, HSTL profiles appeared to be closer to that of NKTCL, another extranodal entity derived from cytotoxic cells, than that of PTCL,NOS and AITL.
Compared to both PTCL, NOS and NKTCL, several T-cell associated transcripts encoding the γδ T-cell receptor (TCR) subunit were among the top genes overexpressed in HSTL. Two of the interesting genes found to be upregulated in HSTL were S1PR5, a gene known to be involved in the homing of NK cells into the spleen 27 and ABCB1 encoding for the p-glycoprotein multidrug transporter (MDR1). These findings were confirmed by qRT-PCR that demonstrated high S1PR5
and ABCB1 transcripts in HSTL compared to PTCL,NOS and NKTCL ( Figure 2 ). Genes encoding KIRs and other NK cell-associated molecules (NCAM1, CD244) were specifically overexpressed compared to PTCL, NOS (Tables 2 and 3) .
AIM1, reported as a tumor suppressor gene 28 , was underexpressed in HSTL compared both to PTCL,NOS and NKTCL. The genes underexpressed in HSTL compared to PTCL,NOS included genes encoding T FH -associated molecules (CXCL13, ICOS, CD200, CXCR5), others involved in immunomodulation (IDO1, IL4I1) as well as CD5, a T-cell surface antigen known to be absent in HSTL cells.
-Candidate genes relevant to HSTL pathogenesis
To search for candidate genes relevant to the pathogenesis of HSTL, we compared HSTL signature to that of normal γδ T cells. A selection of significantly overexpressed and underexpressed genes distinguishing HSTL from normal activated or resting γδ T cells is summarized in Table 4 Interestingly, many of these genes appeared to be also overexpressed in HSTL sorted cells compared to normal activated or resting cells γδ T cells (supplemental Table S1 ). This was the case for genes encoding FOS, VAV3, RHOB, S1PR5 and NK-cell associated molecules indicating that their overexpression could be attributed to the neoplastic cells. Genes associated with cytotoxicity (Granulysin, Granzyme H, Granzyme K, Granzyme B), cytokines (LTA, TNF, IFNG), the tumor suppressor AIM1 and CD5 were among genes those significantly underexpressed in HSTL compared to normal cell counterpart. Absence of expression of cytotoxic molecules such as Granzyme B (Table 1) and Granzyme H was shown by immunostaining ( Figure 3H ) whereas the dramatic reduction of AIM1 transcripts was demonstrated by qRT-PCR in both HSTL tissues and sorted cells compared to normal γδ cells ( Figure 5A ).
-Biomarkers discriminating HSTL from other lymphomas and normal controls
Expression of several genes in the molecular signature of HSTL appeared most likely to be attributed to the normal spleen signature. This is the case of ICAM-1, VCAM-1 and CD163 gene products, whose expression was shown by immunohistochemistry to be restricted to non HSTL from other lymphomas entities and normal controls (Supplemental Figure S2 and tables S2, S3 and S4). Among these genes were those encoding KIR molecules (KIR3DS1), CD244, DTNBP1 and S1PR5. The application of this list of biomarkers to an independent series of lymphoma samples (including 4 HSTL, 15 AITL and 11 PTCL,NOS) using a different plateform 17 allowed discrimination of HSTL from other PTCLs (supplemental Figure S3 ).
-Relevant pathways and genes potentially involved in HSTL resistance to therapy
Pathways analyses showed significant enrichment of a number of pathways which are involved in cancer development or can be the target of innovative treatments, such as VEGF, MAP kinase, JAK-STAT, mTOR, Notch signaling pathways, cytokine-cytokine receptor interaction, cell adhesion (Table 6 and supplemental table S5 ). The Wnt signature was found deregulated but activation of the pathway was not supported by immunohistochemistry since the expression of β-catenin was restricted to endothelial cells. Consistent with previous findings 17 , pathways related to NK-cell mediated cytotoxicity were among the most differentially expressed compared to other T-cell lymphoma entities and normal γδ T cells ( Figure 4A ). Furthermore, as illustrated in 
-Isochromosome 7 q is the main recurrent genomic aberration in HSTL
The aCGH findings confirmed recurrent isochromosome 7q in 4 of the seven tested cases (60%), with only few other alterations comprising trisomy 8 as previouly reported 9 , loss of 10p arm and more focal alterations (-14q,+15q, -18q -21q, -22q) in 2 to 6 cases (30-85%)(Supplemental figure   S4 ). In order to determine whether iso7q impacts on the molecular signature, we analysed the mean expression of genes located on the 7p and 7q arms for each sample (Supplemental figure   S5 ). This analysis clearly showed overexpression of 7q and down expression of 7p genes in all cases with iso7q aberration as well as in 2 additional cases (HSTL_08, HSTL_09) for which the iso7q status was unknown (absence of aCGHa and FISH data), one of which could be subsequently demonstrated as iso7q by FISH (HSTL_09). To identify potential candidate genes involved in iso7q, we further compared the expression level of iso7q+ HSTL cases to normal controls (i.e. activated γδ T cells). Among the most repressed genes on 7p arm were CYCS, IKZF1 associated to regulation of apoptosis and HUS1, CBX3 involved in DNA repair, while the most overexpressed genes on 7q arm included the putative oncogene PTPN12 (Supplemental Table S1 ). Moreover, pathway analysis comparing iso7q+ HSTL to activated or resting γδ T cells showed a significant enrichment of apoptosis-related pathways (Supplemental Table S5 ).
-AIM1 is methylated in HSTL
AIM1 (absent in melanoma 1), initially described as a tumor suppressor gene deleted in melanoma, was subsequently found to be deregulated in NKTCL 28, 30 . Here we show significant downexpression of AIM1 mRNA in HSTL and DERL2 cells. Low levels of AIM1 mRNAs were confirmed by qRT-PCR in HTSL primary tumors and in DERL2 cells compared to normal γδ T cells ( Figure 5A ). We further searched for genetic alterations underlying AIM1 downregulation.
In the absence of genomic imbalance in AIM1 locus at 6q21 in aCGH data, we asked whether AIM1 downregulation in HSTL could be the result of methylation as already reported in other hematologic malignancies such as myeloma and NKTCL 30, 31 . The promoter methylation status of AIM1 was analysed in the HSTL-derived cell line, DERL-2. Sequencing of AIM1 on bisulfitetreated DNA revealed methylation in both CpG islands ( Figure 5B) . Furthermore, the treatment of DERL2 cells with AIM1 methylated promoter with the DNA demethylating agent decitabine with or without TSA resulted in a 2-3 fold increase in AIM1 mRNA level compared to untreated cells, supporting that AIM1 downexpression in HSTL could be reversed by demethylation ( Figure   5C ). Interestingly, the number of DERL2 apoptotic cells was increased after decitabine treatment ( Figure 5D ).
-Syk as a candidate target for pharmacologic inhibition in HSTL
Whereas normal mature T lymphocytes lack Syk expression, Syk protein has been recently reported to be aberrantly expressed in many PTCLs 32 . GEP analysis revealed overexpression of 
16
T cells has especially been reported in patients with kidney transplantation, systemic lupus, Hodgkin lymphoma or malaria 4 and more recently also after treatment with anti-TNF agents 36 .
The elective distribution of the neoplastic cells within the sinuses and sinusoids of the bone marrow, spleen and liver is remarkable and accounts for the peculiar clinical presentation of HSTL with hepatosplenomegaly and cytopenia but without lymphadenopathy and leukemic pictures. Interestingly, one of the gene with the highest fold change of expression compared to PTCL,NOS and NKTCL and to a lesser extend in normal γδ T cells was Sphingosine-1-phosphatase receptor 5 (S1PR5). S1PR5 encodes a member of the family of S1P receptors known to be involved in T-and B-cell exit from lymphoid organs 37 . S1PR5 is preferentially expressed by mature CD56 dim human NK cells 38 and is involved in NK cell trafficking in steady-state and inflammatory situations. It has been reported that S1PR5-deficient mice have defective homing of NK cells to blood and spleen 27, 38 . Although the role of S1PR5 in γδ T cells is uncharacterized, the high level of S1PR5 mRNA in HSTL might explain the peculiar distribution and accumulation of neoplastic γδ cells in the spleen and bone marrow, preventing tumor cells from exiting sinusoids. Whether cell-cell interaction involving the cell adhesion molecule LFA1 (CD11a) expressed by HSTL cells and VCAM1 expressed by splenic sinusoidal cells could also play a role in the clinicopathologic picture of the disease remains to be determined.
Although our GEP findings were based on the comparison with normal blood γδ T cells
and not with splenic γδ T cells, the down or overexpression of selected genes compared to normal splenic γδ T cells was validated by qRT-PCR. From the present study it appears that several candidate genes involved in distinct pathways (i.e. TCR signalling, cell cycle, sonic hedgehog, sprouty regulation of tyrosine kinase pathways and multi-drug resistance) could potentially be associated with the pathophysiology of HSTL. One of the genes we found overexpressed in HSTL is MDR-1, whose expression was significant for this lymphoma upon comparison with normal γδ T cells, PTCL,NOS and NKTCL. The P-Glycoprotein (P-gp), encoded by MDR-1, is able to export drugs out of the cytoplasm, thus reducing the intracellular accumulation of cytotoxic drugs. P-gp has been reported to be overexpressed and associated with poor outcome in various hematological malignancies including NKTCL and in DLBCL 39, 40, 41 . Interestingly, sensitivity to aracytine is not influenced by P-gp overexpression in multidrug resistant cell lines 42 . Although HSTL is reported as a fatal disease, recent reports have described long survivors after cytarabine-based chemotherapy 4 . The present findings might provide a rationale for the use of cytarabine containing regimen in HSTL. In addition to P-gp expression we demonstrated that Glutathione-S-transferases (GSTs), another molecule involved with resistance to alkylating agents and anthracyclines 43 was also expressed by the neoplastic HSTL cells (as shown by immunohistochemistry). One could hypothesise that the combination of P-gp and GSTpi expression might contribute to the resistance to anthracyclin-based chemotherapy regimen of HSTL and its poor outcome. High levels of GST-pi are reported in neoplastic cells of mantle cell lymphoma and DLBCL 44, 45 and are correlated with poor prognosis in DLBCL 44 . The role of transcription factor Blimp-1 in PTCL is unclear. We show here that PRDM1 is expressed at mRNA and protein level in HSTL cells. While inactivation of PRDM1 through epigenetic mechanisms has been recently reported in NKTCL suggesting a role as tumor suppressor gene 30, 46 , its expression has been associated with chemoresistance in T-cell lymphoma 29 .
Tumor development is a multistep process involving deregulation of oncogenes and tumor suppressor genes (TSG). To date, no oncogene or TSG has been identified in HSTL. AIM1 is a gene whose expression is altered in association with tumor suppression in a model of human melanoma 28 . It is frequently deleted or methylated in several solid tumors and in myeloma and more interestingly NK cell lines 14, 30, 31 . Altogether, these data and our findings that AIM1 is dramatically reduced in HSTL most likely due to promoter methylation suggest that AIM1 might play a role as a TSG in HSTL oncogenesis and provide rationale for testing demethylating agents 18 in this disease. Our expression data also suggests that the recurrent iso7q aberration in HSTL could target putative TSG and oncogenes, including IKZF1 and PTPN12. (*) HSTL_02 with a γδ HSTL phenotype at diagnosis disclosed a TCR-silent phenotype (βF1-, δTCR1-) at the time of analysis. (**) δ chain rearrangement determination using a GC-clamp multiplex polymerase chain reaction (PCR)-δ-DGGE procedure (°) EBV investigation by in situ hybridization with EBERs probes and/or immunohistochemistry with LMP-1 antibody 24 * genes also differentially expressed in HSTL cells compared to normal activated γδ T cells. ° genes also differentially expressed in HSTL cells compared to normal resting γδ T cells. 
